287 related articles for article (PubMed ID: 30372737)
1. Diquafosol Sodium Inhibits Apoptosis and Inflammation of Corneal Epithelial Cells Via Activation of Erk1/2 and RSK: In Vitro and In Vivo Dry Eye Model.
Park JH; Moon SH; Kang DH; Um HJ; Kang SS; Kim JY; Tchah H
Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):5108-5115. PubMed ID: 30372737
[TBL] [Abstract][Full Text] [Related]
2. Diquafosol ophthalmic solution for dry eye treatment.
Nakamura M; Imanaka T; Sakamoto A
Adv Ther; 2012 Jul; 29(7):579-89. PubMed ID: 22843206
[TBL] [Abstract][Full Text] [Related]
3. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
Hwang HS; Sung YM; Lee WS; Kim EC
Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152
[TBL] [Abstract][Full Text] [Related]
4. Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition.
Shigeyasu C; Yamada M; Akune Y; Tsubota K
Jpn J Ophthalmol; 2015 Nov; 59(6):415-20. PubMed ID: 26310103
[TBL] [Abstract][Full Text] [Related]
5. Diquafosol promotes corneal epithelial healing via intracellular calcium-mediated ERK activation.
Byun YS; Yoo YS; Kwon JY; Joo JS; Lim SA; Whang WJ; Mok JW; Choi JS; Joo CK
Exp Eye Res; 2016 Feb; 143():89-97. PubMed ID: 26505315
[TBL] [Abstract][Full Text] [Related]
6. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S
Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526
[TBL] [Abstract][Full Text] [Related]
7. Effects of Diquafosol Ophthalmic Solution on Quality of Life in Dry Eye Assessed Using the Dry Eye-Related Quality-of-Life Score Questionnaire: Effectiveness in Patients While Reading and Using Visual Display Terminals.
Utsunomiya T; Kawahara A; Hanada K; Yoshida A
Cornea; 2017 Aug; 36(8):908-914. PubMed ID: 28542084
[TBL] [Abstract][Full Text] [Related]
8. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
Yamane M; Ogawa Y; Fukui M; Kamoi M; Saijo-Ban Y; Yaguchi S; Mukai S; Kawakita T; Simmura S; Tsubota K
Optom Vis Sci; 2015 Apr; 92(4 Suppl 1):S25-32. PubMed ID: 25785527
[TBL] [Abstract][Full Text] [Related]
9. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.
Keating GM
Drugs; 2015 May; 75(8):911-22. PubMed ID: 25968930
[TBL] [Abstract][Full Text] [Related]
10. Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye.
Koh S; Maeda N; Ikeda C; Oie Y; Soma T; Tsujikawa M; Watanabe H; Nishida K
Acta Ophthalmol; 2014 Dec; 92(8):e671-5. PubMed ID: 24863298
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis.
Toda I; Ide T; Fukumoto T; Ichihashi Y; Tsubota K
Am J Ophthalmol; 2014 Mar; 157(3):616-22.e1. PubMed ID: 24528935
[TBL] [Abstract][Full Text] [Related]
12. Effect of Diquafosol on Hyperosmotic Stress-induced Tumor Necrosis Factor-α and Interleukin-6 Expression in Human Corneal Epithelial Cells.
Kim YH; Yang IJ; Nguyen LTH; Gum SI; Yu S; Lee GJ; Kim BA; Jung JC; Park YJ
Korean J Ophthalmol; 2020 Feb; 34(1):1-10. PubMed ID: 32037744
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients.
Zheng Q; Ren Y; Reinach PS; Xiao B; Lu H; Zhu Y; Qu J; Chen W
Exp Eye Res; 2015 May; 134():133-40. PubMed ID: 25701684
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye.
Koh S; Ikeda C; Takai Y; Watanabe H; Maeda N; Nishida K
Jpn J Ophthalmol; 2013 Sep; 57(5):440-6. PubMed ID: 23740285
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
[TBL] [Abstract][Full Text] [Related]
16. Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Park DH; Chung JK; Seo DR; Lee SJ
Am J Ophthalmol; 2016 Mar; 163():122-131.e2. PubMed ID: 26685791
[TBL] [Abstract][Full Text] [Related]
17. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore.
Gong L; Sun X; Ma Z; Wang Q; Xu X; Chen X; Shao Y; Yao K; Tang L; Gu Y; Yuan H; Chua WH; Chuan JC; Tong L
Br J Ophthalmol; 2015 Jul; 99(7):903-8. PubMed ID: 25631485
[TBL] [Abstract][Full Text] [Related]
18. Diquafosol tetrasodium: a novel dry eye therapy.
Nichols KK; Yerxa B; Kellerman DJ
Expert Opin Investig Drugs; 2004 Jan; 13(1):47-54. PubMed ID: 14680452
[TBL] [Abstract][Full Text] [Related]
19. Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye.
Kaido M; Uchino M; Kojima T; Dogru M; Tsubota K
J Ocul Pharmacol Ther; 2013; 29(6):595-603. PubMed ID: 23537148
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials.
Nam K; Kim HJ; Yoo A
Ophthalmic Res; 2019; 61(4):188-198. PubMed ID: 30654362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
